American Clinical Research Services Announces Rebranding to Elixia

American Clinical Research Services (ACRS), a leader in complex clinical research, is proud to announce its rebranding to Elixia, signifying the company’s expanded vision and capabilities in the clinical research and patient recruitment sectors. Elixia is a portfolio company of Latticework Capital Management.

This transition to Elixia signifies more than a name change, embodying the company’s commitment to drug development and healthcare delivery. Elixia combines the robust capabilities of premier clinical research sites with a leading patient recruitment engine, enabling it to support clinical trials with efficiency and precision. The name Elixia was chosen to capture the essence of the company’s mission: to accelerate the development of life-changing therapies and improve patient outcomes worldwide.

“Rebranding to Elixia represents the unification of our diverse strengths under a shared vision,” said Dustin Owen, CEO of Elixia. “Our integrated approach and expanded reach uniquely position us to address the complexities of modern drug development. With Elixia, we are poised to make a profound impact on the healthcare landscape, driving innovations that bring new treatments to patients faster and more effectively than ever before.”

Established in 2022 through the acquisition of Catalina Research Institute, a leader in therapeutically focused clinical research, ACRS has positioned itself as a significant player in the industry. Building on this foundation, ACRS strengthened its services in 2023, acquiring CSSi and Patient Advertising Guru, both prominent companies specializing in patient recruitment. The culmination of these strategic acquisitions is the recent addition of Elixia, whose name will now be adopted for the entire organization. The company remains committed to its partners, patients and stakeholders as it embarks on this exciting new chapter.

About Elixia

Elixia is an industry-leading clinical research entity, linking a vast network of multi-site clinical research facilities with a global patient recruitment operation. With sites in California, Florida, Massachusetts, Missouri, Michigan, and Texas, Elixia conducts Phase I-IV studies, addressing complex conditions in metabolic health, nephrology, neuroscience, and infectious diseases. Elixia is renowned globally for its technological prowess, which enhances efficiency in patient acquisition and offers critical health outcome data that provides invaluable insights to sponsors worldwide. For more information, please visit elixiahealth.com.

About Latticework Capital Management (LCM)

Headquartered in Dallas, TX, Latticework is a growth oriented private equity firm focused exclusively on making control equity investments in the healthcare industry. LCM has completed more than 130 transactions across a diverse array of healthcare subsectors and currently has more than $550 million in assets under management. LCM leverages its more than 100 combined years of healthcare and investing experience, as well as its network of industry executives, to help companies scale and realize their full long-term value. For more information, please visit latticeworkcapital.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716441996/en/